Izaguirre-Ávila R, Cortina-de la Rosa E, García-Espinosa JI, Grimaldo-Gómez FA

Idioma: Español
Referencias bibliográficas: 27
Paginas: 405-408
Archivo PDF: 173.56 Kb.

FRAGMENTO

Introducción

La cirugía cardíaca es un procedimiento que se ha vuelto cada vez más frecuente en México. Se calcula que de los enfermos sometidos a cirugía cardíaca con circulación extracorpórea (CEC), el 20% presentan hemorragia y el 5% requieren de una reintervención exploratoria, aunque sólo se encuentra una causa quirúrgica de la hemorragia en el 50% de los pacientes reoperados. La hemorragia crítica después de CEC es una complicación grave y es el inicio de una serie de fenómenos fisiopatológicos que, si no se modifican oportunamente, pueden conducir a la muerte del paciente. La hemorragia por CEC puede causar otras complicaciones, en particular, mediastinitis, sepsis, coagulación intravascular diseminada (CID), insuficiencia renal aguda (IRA), síndrome de dificultad respiratoria progresiva del adulto, arritmias, etcétera(3). Por ello es conveniente identificar, de ser posible desde la etapa preoperatoria, a los enfermos que podrían desarrollar esta complicación, con el propósito de implementar medidas preventivas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Parr KG, Patel MA, Dekker R, Levin R, Glynn R, Avorn J, Morse DS. Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth. 2003;17(:176-181.

2. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med. 2004;30:1873-1881.

3. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996;111:1037-1046.

4. Woodman RC, Harker L. Bleeding complications associated with cardiopulmonary bypass. Blood. 1990;76:1680-1697.

5. Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost. 1985;11:281-292.

6. Perutelli P, Lerzo F, Calza G, Cevasco M, Mori PG. Abnormalities of plasma von Willebrand factor multimeric structure induced by extracorporeal circulation. Haematologica. 1999;84:287-288.

7. Perutelli P. Proteolysis of von Willebrand factor is increased during cardiopulmonary bypass. Thromb Res. 2001;102:467-473.

8. Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation. 2000;102:1290-1295.

9. Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood. 1986;67:758-761.

10. Guzmán M, Izaguirre R. Alteraciones de las plaquetas en la circulación extracorpórea con distintos tipos de oxigenador [Tesis Doctoral]. Granada: Universidad de Granada, España e Instituto Nacional de Cardiología de México; 1993.

11. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth. 1989;3:181-188.

12. BañosG, De la Peña A, Izaguirre R. The vascular plasminogen activator as source of the fibrinolytic potential observed during cardiopulmonary bypass. Thromb Res. 1992;67:579-588.

13. Nielsen VG. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg. 2006;81:1720-1727.

14. Roherer MJ, Natale AM. Effect of hypothermia on the coagulation cascade. Crit Care Med. 1992;20:1402-1405.

15. Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma. 2004;56:1221-1228.

16. Pifarre R. The importance of proper anticoagulation and heparin neutralization in cardiopulmonary Bypass. In: Pifarre R, ed. Management of bleeding in cardiovascular surgery. Philadelphia: Hanley &Belfus, Inc.; 2000: pp. 101-105.

17. Shander A, Moskowitz D, Rijhwani TS. The safety and efficacy of “bloodless” cardiac surgery. Semin Cardiothorac Vasc Anesth. 2005;9:53-63.

18. Handa A, Dickstein B, Young NS, Brown KE. Prevalence of the newly described human circovirus, TTV, in United States blood donors. Transfusion. 2000;40:245-251.

19. Chambers LA, Kruskall MS. Strategies to limit homologous blood use in cardiac surgery. In: Baldwin ML, Kurtz SR, eds. Transfusion practice in cardiac surgery. Arlington, VA: American Association of Blood Banks; 1991: pp. 13-31.

20. Ferraris VA, Ferraris SP, Joseph O, Wehner P, Mentzer RM Jr. Aspirin and postoperative bleeding after coronary artery bypass grafting. Ann Surg. 2002;235:820-827.

21. Rawitscher RE, Jones JW, McCoy TA, Lindsley DA. A prospective study of aspirin’s effect on red blood cell loss in cardiac surgery. J Cardiovasc Surg (Torino). 1991;32:1-7.

22. Reich DL, Patel GC, Vela-Cantos F, Bodian C, Lansman S. Aspirin does not increase homologous blood requirements in elective coronary bypass surgery. Anesth Analg. 1994;79:4-8.

23. Levy JH. Aspirin and bleeding alter coronary artery bypass grafting. Anest Anal. 1994;79:1-3.

24. Ray JG, Deniz S, Olivieri A, Pollex E, Vermeulen MJ, Alexander KS, et al. Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel. BMC Cardiovasc Disord. 2003;3:3.

25. Anselmi A, Guinet P, Ruggieri VG, Aymami M, Lelong B, Granry S, et al. Safety of recombinant factor VIIa in patients under extracorporeal membrane oxygenation. Eur J Cardiothorac Surg. 2016;49:78-84.

26. Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007;83:707-714.

27. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12:R105.